Cancer Stem Cells and Tumor Response to Therapy: Current Problems and Future Prospects

Seminars in Radiation Oncology

Volumn 19, Issue 2, 2009, Pages 96-105

  Milas, Luka ^a   Hittelman, Walter N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FENRETINIDE; FLAVOPIRIDOL; IMATINIB; MISONIDAZOLE; PROTEIN TYROSINE KINASE INHIBITOR; SU 11657; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL ASSAY; CELL SUBPOPULATION; CLINICAL TRIAL; CLONOGENESIS; DRUG TARGETING; DRUG WITHDRAWAL; HOMEOSTASIS; HUMAN; HYPOXIA; LONG TERM CARE; MICROENVIRONMENT; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANIMALS; DRUG RESISTANCE; HUMANS; MICE; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE;

EID: 60649100252     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2008.11.004     Document Type: Review

References (108)

1. Ang K.K., Peters L.J., Weber R.S., et al. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 19 (1990) 1339-1345
2. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
3. Saunders M., Dische S., Barrett A., et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomized multicentre trial. Radiother Oncol 52 (1999) 137-148
4. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
5. Eisbruch A. Intensity-modulated therapy: A clinical perspective. Introduction. Semin Radiat Oncol (2002) 197-198
6. Jordan C.T., Guzman M.L., and Noble M. Cancer stem cells. N Engl J Med 355 (2006) 1253-1261
7. Houghton J., Morozov A., Smirnova I., et al. Stem cells and cancer. Semin Cancer Biol 17 (2007) 191-203
8. Bissell M.J., and LaBarge M.A. Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment?. Cancer Cells 7 (2005) 17-23
9. Jones D.L., and Wagers A.J. No place like home: Anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol 9 (2008) 11-21
10. Morrison S.J., and Spradling A.C. Stem cells and niches: Mechanisms that promote stem cell maintenance throughout life. Cell 132 (2008) 598-611
11. Barcellos-Hoff M.H., Park C., and Wright E.G. Radiation and the microenvironment-Tumorigenesis and therapy. Nat Rev Cancer 5 (2005) 867-875
12. Baumann M., Krause M., and Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8 (2008) 545-554
13. Wicha M.S., Liu S., and Dontu G. Cancer stem cells: An old idea-A paradigm shift. Cancer Res 66 (2006) 1883-1890
14. Hill R.P. Identifying cancer stem cells in solid tumors: Case not proven. Cancer Res 66 (2006) 1891-1896
15. Tannock I.F. Tumor physiology and drug resistance. Cancer Metastasis Rev 20 (2001) 123-132
16. Withers H.R., Taylor J.M.G., and Maciejewski B. The hazard of accelerated tumors clonogen repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
17. Buick R.N. Radiological and clinical implications of the stem cell concept in human malignancy. In: Cory J.G., and Szentivany A. (Eds). Cancer Biology and Therapeutics (1987), Plenum Publishing, New York, NY 65-76
18. Shelby P., Buick R.N., and Tannock I. A critical appraisal of the "human tumor stem-cell assay. " N Engl J Med 308 (1983) 129-134
19. Hill R.P., and Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 16 (1989) 513-518
20. Baumann M., Dorr W., Petersen C., et al. Repopulation during fractionated radiotherapy: Much has been learned, even more is open. Int J Radiat Biol 79 (2003) 465-467
21. Kern S.E., and Shibata D. The fuzzy math of solid tumor stem cells: A perspective. Cancer Res 67 (2007) 8985-8988
22. Adams J.M., and Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones?. Cancer Res 68 (2008) 4018-4021
23. Revesz L. Effect of lethally damaged tumor cells upon the development of admixed viable cells. J Natl Cancer Inst 20 (1958) 1157-1186
24. Hewitt H., Blake E., and Porter E. The effect of lethally irradiated cells on the transplantability of murine tumours. Br J Cancer 28 (1973) 123-135
25. Milas L., Ito H., Hunter N., et al. Retardation of tumor growth in mice caused by radiation-induced injury of tumor bed stoma: Dependency on tumor type. Cancer Res 46 (1986) 712-727
26. Milas L., and Peters L.J. Conditioning of tissues for metastasis formation by radiation and cytotoxic drugs. In: Nicholson G.L., and Milas L. (Eds). Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects (1984), Raven Press, New York, NY 321-336
27. Li L., and Neaves W.B. Normal stem cells and cancer stem cells: The niche matters. Cancer Res 66 (2006) 4553-4557
28. Polyak K., and Hahn W.C. Roots and stems: Stem cells in cancer. Nat Med 12 (2006) 296-300
29. Blanpain C., Horsley V., and Fuchs E. Epithelial stem cells: Turning over new leaves. Cell 128 (2007) 445-458
30. Fletcher G.H. Textbook of Radiotherapy (1980), Lea & Febiger, Philadelphia, PA
31. Milas L., Yamada S., Hunter N., et al. Changes in TCD50 as a measure of clonogen doubling time in irradiated and unirradiated tumors. Int J Radiat Oncol Biol Phys 21 (1991) 1195-1202
32. Milas L., Nakayama T., Hunter N., et al. Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Radiother Oncol 30 (1994) 247-253
33. Thames H.D., Ruifrock A.C., Milas L., et al. Accelerated repopulation during fractionated irradiation of a murine ovarian carcinoma: Downregulation of apoptosis as a possible mechanism. Int J Radiat Oncol Biol Phys 35 (1996) 951-962
34. Peters L.J., and Ang K.K. The role of altered fractionation in head and neck cancers. Semin Radiat Oncol 2 (1992) 18-194
35. O'Brien C.A., Pollet A., Gallinger S., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007) 106-110
36. Bickenbach J.R., and Chism E. Selection and extended growth of murine epidermal stem cells in culture. Exp Cell Res 244 (1998) 184-195
37. Goodell M.A., Brose K., Paradis G., et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in Vivo. J Exp Med 193 (1996) 1797-1806
38. Jordan C.T. Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol 16 (2004) 708-712
39. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breat cancer cells. PNAS 100 (2003) 3983-3988
40. Molofsky A.V., Pardal R., and Morrison S.J. Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol 16 (2004) 700-707
41. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 63 (2003) 5821-5828
42. Hammati H.D., Nakano I., Lazareff J.A., et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100 (2003) 15178-15183
43. Jin L., Hope K.J., Zhai Q., et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12 (2006) 1167-1174
44. Crosnier C., Stamataki D., and Lewis J. Organizing cell renewal in the intestine: Stem cells, signals and combinatorial control. Nat Rev Genet 7 (2006) 349-359
45. Williams D.A., and Cancelas J.A. Leukaemia: Niche retreats for stem cells. Nature 444 (2006) 827-828
46. Beachy P.A., Karhadkar S.S., and Berman D.M. Tissue repair and stem cell renewal in carcinogenesis. Nature 432 (2004) 324-331
47. Henrique D., Hirsinger E., Adam U., et al. Maintenance of neuroepithelial progenitor cells by delta-notch signaling in the embryonic chick retina. Curr Biol 7 (1997) 661-670
48. Calvi L.M., Adams G.B., Weibrecht K.W., et al. Osteoblastic cells regulate the hematopoietic stem cell niche. Nature 435 (2003) 841-846
49. Battle E., Henderson J.T., Beghtel H., et al. β-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111 (2002) 251-263
50. Van de Wetering M., Sancho E., Verweij C., et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111 (2002) 241-250
51. Lai K., Kaspar B.K., Gage F.H., et al. Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci 6 (2003) 21-27
52. Kai T., and Spradling A. An empty drosophila stem cell niche reactivates the proliferation of ectopic cells. Proc Natl Acad Sci U S A 100 (2003) 4633-4638
53. Evangelista M., Tian H., and de Sauvage J. The hedgehog signaling pathway in cancer. Clin Cancer Res 12 (2006) 5924-5928
54. Hall E.J. Radiobiology for the Radiologist. ed 5 (2000), Lippincott Williams & Wilkins, New York, NY
55. Keith B., and Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 129 (2007) 465-472
56. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
57. Rich J. Cancer stem cells in radiation resistance. Cancer Res 67 (2007) 8980-8984
58. Hambardzumyan D., Becher O.J., Rosenblum M.K., et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22 (2008) 436-448
59. Brown J.M. Tumor hypoxia in cancer therapy. Methods Enzymol 435 (2007) 297-321
60. Hardee M.E., Arcasoy M.O., Blackwell K.L., et al. Erythropoietin biology in cancer. Clin Cancer Res 12 (2006) 332-339
61. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285 (1971) 1182-1186
62. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
63. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
64. Kerbel R.S. Antiangiogenic therapy: A universal chemosensitization strategy for cancer?. Science 312 (2006) 1171-1175
65. Teicher B.A., Holden S.A., Dupuis N.P., et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 36 (1995) 227-236
66. Kakeji Y., and Teicher B.A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest N Drugs 15 (1997) 39-48
67. Jain R.K. Normalizing tumor vasculature with antiangiogenic therapy: A new paradigm for combination therapy. Nat Med 7 (2001) 987-989
68. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoitin-1, and matrix metalloproteinases. Cancer Cells 6 (2004) 553-563
69. Ansiaux R., Baudelet C., Jordan B.F., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11 (2005) 743-750
70. Huber P.E., Bischof M., Jenne J., et al. Trimodel cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65 (2005) 3643-3655
71. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
72. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
73. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
74. Goitein M., and Cox J.D. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol 26 (2008) 175-176
75. Baselga J. Targeting tyrosine kinases in cancer: The second wave. Science 312 (2006) 1175-1178
76. Tse A.N., Carvajal R., and Schwartz G.K. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 13 (2007) 1955-1960
77. Michor F., Hughes T.P., Iwasa Y., et al. Dynamics of chronic myeloid leukaemia. Nature 435 (2005) 1267-1270
78. Milas L., Mason K.A., and Ang K.K. Epidermal growth factor receptor and its inhibition in radiotherapy: In-vivo findings. Int J Radiat Biol 79 (2003) 539-545
79. Schmidt-Ullrich R.K., Dent P., Grant S., et al. Signal transduction and cellular radiation responses. Radiat Res 153 (2000) 245-257
80. Schmidt-Ullrich R.K., Mikkelsen R.B.D.P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
81. Milas L., Mason K., Hunter N., et al. In-vivo enhancement of tumor radio response by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6 (2000) 701-708
82. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
83. Mendelsohn J. Blockade of receptors for growth factors: An anticancer therapy. The fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Research award lecture. Clin Cancer Res 6 (2000) 747-753
84. Nasu S., Ang K.K., Fan Z., et al. C225 antiepidermal growth factor receptor antibody enhances tumor radio curability. Int Radiat Oncol J Biol Phys 51 (2001) 474-477
85. Raben D., Bianco C., Milas L., et al. Targeted therapies and radiation for the treatment of head and neck cancer: Are we making progress?. Semin Radiat Oncol 14 (2004) 139-152
86. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
87. Krause M., Ostermann G., Petersen C., et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76 (2005) 162-167
88. Dittmann K., Mayer C., Fehrenbacher B., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280 (2005) 31182-31189
89. Halazonetis T.D., Gorgoulis V.G., and Bartek J. An oncogene-induced DNA damage model for cancer development. Science 319 (2008) 1352-1355
90. Milas L., Akimoto T., Hunter N.R., et al. Relationship between cyclin D1 expression and poor radio response of murine carcinomas. Int J Radiat Oncol Biol Phys 52 (2002) 514-521
91. Mason K.A., Hunter N.R., Raju U., et al. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radio response. Int J Radiat Oncol Biol Phys 59 (2004) 1181-1189
92. Raju U., Nakata E., Mason K.A., et al. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 63 (2003) 3263-3267
93. Sedlacek H.H. Mechanisms of action of flavopiridol. Crit. Rev Oncol 38 (2001) 139-170
94. Chen Y.J., Sims-Mourtada J., Izzo J., et al. Targeting the hedgehog pathway to mitigate treatment resistance. Cell Cycle 6 (2007) 1826-1830
95. Zhu G.Y., Cao X.Y., Chang J.Y., et al. Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol Rep 18 (2007) 645-651
96. 3H mouse fibrosarcoma. Radiat Res 45 (1970) 41-49
97. Milas L., Hunter N., and Peters L.J. The tumor bed effect: Dependence of tumor take, growth rate, and metastasis on the time interval between irradiation and tumor cell transplantation. Int J Radiat Oncol Biol Phys 13 (1987) 379-383
98. Milas L. Tumor bed effect in murine tumors: Relationship to tumor take and tumor macrophage content. Radiat Res 123 (1990) 232-236
99. Riesterer O., Pickett J., Patel N., et al. Tumor bed irradiation enhances sensitivity of A431 tumor xenografts to C225 anti-EGFR antibody. Proc Am Assoc Cancer Res 49 (2008) abstr. No. 1318
100. Tredan O., Galmarini C.M., Patel K., et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99 (2007) 1441-1154
101. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
102. Hicklin D.J., and Ellis L.M. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1127
103. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59 (1994) 471-482
104. O'Reilly M.S., Holmgren L., Chen C., et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2 (1996) 689-692
105. Milas L., Fang F.M., Mason K.A., et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 67 (2007) 568-572
106. Choy H., and Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A Rational Advance?. J Natl Cancer Inst 95 (2003) 1440-1452
107. Milas L., Furuta Y., Hunter N., et al. Dependence of indomethacin-induced potentiation of murine tumor radio response on tumor host immunocompetence. Cancer Res 50 (1990) 4473-4477
108. Skipper H.E., Schabel F.M., and Wilcox W.S. Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35 (1964) 1-111